← All Astrazeneca PLC filings

Astrazeneca PLC Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

NYSE
AZN
Astrazeneca PLC
SCHEDULE: AstraZeneca Maintains 8.3% Stake in Innate Pharma
AstraZeneca PLC, through its subsidiary MedImmune Limited, has reaffirmed its 8.3% beneficial ownership in Innate Pharma SA.
NYSE
AZN
Astrazeneca PLC
SCHEDULE: AstraZeneca Increases Stake in Cellectis to 44% Following Convertible Share Acquisition
AstraZeneca and its subsidiary now hold a 44% stake in Cellectis after converting preferred shares, with the ability to resell these shares publicly.